Core Laboratories

CLB

Market cap $905M

CLB shows consistent growth, a strong market position and proprietary tech, but faces challenges like cost pressure, international risks and high valuation concerns.

HOUSTON, Jan. 5, 2026 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its fourth quarter 2025 conference call for investors and analysts at 7:30 a.m. CST / 8:30 a.m. EST on February 5, 2026.

CLB benefits from long-term industry investments and strong acquisitions, though its growth is modest and vulnerable to macroeconomic and geopolitical uncertainties.

CLB beats Q3 earnings estimates on strong Production Enhancement results. However, earnings dip y/y due to the Reservoir Description segment's weakness.

Supplier of residential thermal, comfort and security solutions, Resideo Technologies, Inc. (REZI) was the top contributor in the quarter. Shares of gold mining company, Barrick Mining Corporation (B) also jumped in the quarter on strong financial results buoyed by rising gold prices. We added Arthur J. Gallagher & Co. (AJG), the world's largest insurance broker focused on middle-market clients.

Core Laboratories Inc. (NYSE:CLB ) Q3 2025 Earnings Call October 23, 2025 8:30 AM EDT Company Participants Lawrence Bruno - Chairman of the Board, CEO, President & COO Gwendolyn Schreffler - Senior Vice President of Corporate Development & Investor Relations Chris Hill - Senior VP & CFO Conference Call Participants John Daniel - Daniel Energy Partners, LLC Presentation Operator Good day, and welcome to the Core Laboratories Q3 2025 Earnings Call. [Operator Instructions] Please note, this event is being recorded.

Core Laboratories (CLB) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.25 per share a year ago.

HOUSTON, Oct. 22, 2025 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported third quarter 2025 revenue of $134,500,000. Core's operating income was $20,900,000, with earnings per diluted share ("EPS") of $0.30, all in accordance with U.S. generally accepted accounting principles ("GAAP"). Operating income, ex-items, a non-GAAP financial measure, was $16,600,000, yielding operating margins of 12%, sequential incremental margins of 48%, and EPS, ex-items, of $0.22. A full reconciliation of non-GAAP financial measures is included in the attached financial tables.

CLB is set to post Q3 earnings amid volatile oil markets, with estimates hinting at lower revenues and profit declines.

Core Laboratories (CLB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.